Evidence map›Paper›PMID 42100433›Full record

SynthesisFrontiers in oncology2026

Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis.

Ziqian Zhao, Hongyi Yuan, Haoyi Xu, Yuanjing Liu, Rui Xu, Kang Yan, Haojie Tang, Fanchao Dai, Yiming Wu, Chao Dong and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ziqian ZhaoThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Hongyi YuanThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Haoyi XuThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Yuanjing LiuThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Rui XuThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Kang YanThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Haojie TangThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Fanchao DaiThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Yiming WuThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Chao DongThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Binlin MaThe Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The prognostic value of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index for survival outcomes in patients with solid tumors is evaluated through a systematic review and meta-analysis. Methods: We conducted comprehensive searches in PubMed, EMBASE, Cochrane Library and Web of Science for all records published up to February 2026. Hazard ratios (HRs) with 95% confidence intervals (CIs) were retrieved. The associations between pretreatment CALLY and survival endpoints were synthesized using Stata 18.0 and Review Manager 5.4. Overall survival (OS) was the main endpoint; disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS) were also assessed. Results: Fifty-six reports (64 cohorts) comprising 26, 643 individuals were included. A higher CALLY index was correlated with superior OS (HR, 0.55; 95% CI, 0.50-0.60; P<0.00001), DFS (HR, 0.52; 95% CI, 0.46-0.58; P < 0.00001), PFS (HR, 0.39; 95% CI, 0.25-0.61; P<0.0001), and RFS (HR, 0.66; 95% CI, 0.60-0.72; P < 0.00001). Subgroup analyses revealed that effect estimates may be modified by sample size, follow-up duration, age, geographic region, CALLY cut-off values, cancer type, and tumor stage. Conclusions: A higher CALLY score is significantly associated with improved survival outcomes in patients with cancer, indicating its potential as a promising prognostic biomarker.

Indexed as

biomarkerCALLY indexcancermeta-analysisprognosis

Identifiers

PMID42100433
PMCPMC13143774

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.